Hypertension Induced by Immunosuppressive Drugs: A Comparative Analysis Between Sirolimus and Cyclosporine

Transplantation Proceedings

Volumn 41, Issue 3, 2009, Pages 868-873

  Reis, F ^a   Parada, B ^a,b   Teixeira de Lemos, E ^a   Garrido, P ^a   Dias, A ^a   Piloto, N ^a   Baptista, S ^a   Sereno, J ^a   Eufrasio P ^b   Costa, E ^e,f   Rocha Pereira, P ^c,e   Santos Silva, A ^d,e   Figueiredo, A ^b   Mota, A ^b   Teixeira, F ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

^f CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CHOLESTEROL; CYCLOSPORIN A; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN; SEROTONIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ERYTHROCYTE; ERYTHROCYTE LEVEL; HEART RATE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HYPERTENSION; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE VOLUME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOOD PRESSURE; CYCLOSPORINE; DIASTOLE; HEART RATE; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; RATS; RATS, WISTAR; SIROLIMUS; SYSTOLE;

EID: 64649096675     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.02.005     Document Type: Article

References (39)

1. Cortesini R. Cyclosporine-lessons from the first 20 years. Transplant Proc 36 2 suppl (2004) 158S
2. Vitko S., and Viklicky O. Cyclosporine renal dysfunction. Transplant Proc 36 2 suppl (2004) 243S
3. Textor S.C., Taler S.J., Canzanello V.J., et al. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 6 (2000) 521
4. Reis F., Almeida L., Alcobia T., et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3′,5′-monophosphate disturbances. Thromb Res 110 (2003) 107
5. Santiago M., Reis F., Almeida L., et al. Impairment of vascular and platelet nitric oxide and 3′,5′ cyclic guanosine monophosphate content in cyclosporin A-induced hypertensive rats. Fund Clin Pharmacol 17 (2003) 43
6. Reis F., Teixeirade Lemos E., Almeida L., et al. Dual effect of nitrate therapy for cyclosporin-induced hypertension on vascular and platelet morphofunctional markers. Transplant Proc 39 (2007) 2501
7. Reis F., Rocha-Pereira P., Teixeira de Lemos E., et al. Oxidative stress in cyclosporin-induced hypertension: evidence of beneficial effects or tolerance development with nitrate therapy. Transplant Proc 39 (2007) 2494
8. Mota A., Arias M., Taskinen E.I., et al. Rapamune maintenance regimen trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953
9. Parada B., Mota A., Nunes P., et al. Calcineurin inhibitor-free immunosuppression in renal transplantation. Transplant Proc 37 (2005) 2759
10. Moro J., Almenar L., Martínez-Dolz L., et al. mTOR inhibitors: do they help preserve renal function?. Transplant Proc 39 (2007) 2135
11. Chen J., Li L., Wen J., et al. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. Transplant Proc 40 (2008) 1411
12. Groth C.G., Bäckman L., Morales J.M., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67 (1999) 1036
13. Merkel S., Mogilevskaja N., Mengel M., et al. Side effects of sirolimus. Transplant Proc 38 (2006) 714
14. Marti H.P., and Frey F.J. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 20 (2005) 13
15. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
16. Jensen G.S., Wiseman A., and Trotter J.F. Sirolimus conversion for renal preservation in liver transplantation: not so fast. Liver Transpl 14 (2008) 601
17. DuBay D., Smith R.J., Qiu K.G., et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 14 (2008) 651
18. Boratyńska M., Banasik M., Watorek E., et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 38 (2006) 101
19. Kokado Y., Takahara S., Kamoeka H., et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. Transplant Proc 28 (1996) 1600
20. Cosio F.G., Falhenhain M.E., Pesavento T.E., et al. Relationship between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 29 (1997) 419
21. Morath C., Arns W., Schwenger V., et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 22 suppl 8 (2007) viii61
22. Sander M., Lyson T., Thomas G.D., et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 9 (1996) 121S
23. Sander M., and Victor R.G. Hypertension after cardiac transplantation: pathophysiology and management. Curr Opin Nephrol Hypertens 4 (1995) 443
24. Olyaei A.J., de Mattos A.M., and Bennett W.M. A practical guide to the management of hypertension in renal transplant recipients. Drugs 58 (1999) 1011
25. Reis F., Rocha L., Ponte L., et al. Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sci 77 (2005) 2514
26. Saldeen T., Li D., and Mehta J.L. Differential effects of α- and γ-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 34 (1999) 1208
27. Miller N.J., Rice-Evans C., Davies M.J., et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 84 (1993) 407
28. Kahan B.D., Julian B.A., Pescovitz M.D., et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68 (1999) 1526
29. Morales J.M. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl 82 (2002) S81
30. Legendre C., Campistol J.M., Squifflet J.P., et al. Sirolimus European Renal Transplant Study Group: cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 35 3 suppl (2003) 151S
31. Kniepeiss D., Iberer F., Schaffellner S., et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 18 (2004) 642
32. Hong J.C., and Kahan B.D. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69 (2000) 2085
33. Reis F., Tavares P., Rito L.C., et al. Platelet activation is increased in cyclosporin A-induced hypertensive rats. J Cardiovasc Pharmacol 36 (2000) 56
34. López-Ongil S., Hernández-Perera O., Navarro-Antolín J., et al. Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br J Pharmacol 124 (1998) 447
35. Vetter M., Chen Z.J., Chang G.D., et al. Cyclosporin A disrupts bradykinin signaling through superoxide. Hypertension 41 (2003) 1136
36. Dawson T.M., Steiner J.P., Dawson V.L., et al. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A 90 (1993) 9808
37. Gardiner S.M., March J.E., Kemp P.A., et al. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol 141 (2004) 634
38. Zhang W., and Victor R.G. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens 13 (2000) 999
39. Taler S.J., Textor S.C., Canzanello V.J., et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 20 (1999) 437